{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:01:17Z","timestamp":1762408877205},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T00:00:00Z","timestamp":1337731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Compare the risk of secondary cancer versus benefits of maintenance therapy for women with ovarian cancer who have a complete response to pegylated liposomal doxorubicin.Explain the need to perform regular and frequent oral examinations in women with ovarian cancer who received treatment with pegylated liposomal doxorubicin.<\/jats:p>\n                  <jats:p>CME This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Purpose.<\/jats:title>\n                  <jats:p>To describe occurrences of oral squamous cell carcinoma (SCC) in patients who had received long-term pegylated liposomal doxorubicin (PLD) for ovarian cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>In our cohort of patients on maintenance PLD for ovarian and related mullerian epithelial malignancies, we encountered two patients with invasive SCC of the oral cavity (one of them multifocal) and one with high-grade squamous dysplasia. Review of patients at our institution receiving PLD for recurrent ovarian cancer identified three additional patients. The duration of treatment, cumulative PLD dose, human papillomavirus (HPV) positivity, BRCA status, stage at diagnosis, outcome, and other characteristics are reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>All five cases were nonsmokers with no known risk factors for HPV and four were negative for p16 expression. Four of the patients had known BRCA mutations whereas one tested negative. Cumulative doses of PLD were &amp;gt;1,600 mg\/m2 given over 30\u2013132 months. Three had SCCs staged as T1N0 oral tongue, alveolar ridge (gingival), and multifocal oral mucosa; one had a T2N0 oral tongue; and one had dysplasia. After excision, two were given radiation but recurred shortly thereafter; the others remain well and have had no further exposure to cytotoxic drugs, including PLD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Awareness of this possible long-term complication during PLD treatment should enhance the likelihood of early detection of oral lesions in these patients. Decisions to continue maintenance PLD after complete response of the original cancer should perhaps consider the benefits of delaying ovarian cancer recurrence versus the possible risk for a secondary cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0216","type":"journal-article","created":{"date-parts":[[2012,5,24]],"date-time":"2012-05-24T00:48:26Z","timestamp":1337820506000},"page":"1541-1546","source":"Crossref","is-referenced-by-count":36,"title":["Squamous Cell Carcinoma of the Oral Cavity in Nonsmoking Women: A New and Unusual Complication of Chemotherapy for Recurrent Ovarian Cancer?"],"prefix":"10.1093","volume":"17","author":[{"given":"Timothy L.","family":"Cannon","sequence":"first","affiliation":[{"name":"NYU Cancer Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic W.","family":"Lai","sequence":"additional","affiliation":[{"name":"NYU Cancer Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hirsch","sequence":"additional","affiliation":[{"name":"NYU Cancer Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Delacure","sequence":"additional","affiliation":[{"name":"NYU Cancer Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Downey","sequence":"additional","affiliation":[{"name":"NYU Cancer Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R.","family":"Kerr","sequence":"additional","affiliation":[{"name":"NYU Cancer Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bannan","sequence":"additional","affiliation":[{"name":"NYU Cancer Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Andreopoulou","sequence":"additional","affiliation":[{"name":"NYU Cancer Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Safra","sequence":"additional","affiliation":[{"name":"NYU Cancer Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Muggia","sequence":"additional","affiliation":[{"name":"NYU Cancer Institute, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,5,23]]},"reference":[{"key":"2021122308242481500_B1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3109\/02841869409121767","article-title":"Secondary malignancies following cancer chemotherapy","volume":"33","author":"Boffetta","year":"1994","journal-title":"Acta Oncol"},{"key":"2021122308242481500_B2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/oxfordjournals.annonc.a058121","article-title":"Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: From the bedside to the target genes","volume":"3","author":"Ratain","year":"1992","journal-title":"Ann Oncol"},{"key":"2021122308242481500_B3","doi-asserted-by":"crossref","first-page":"11014","DOI":"10.1073\/pnas.0704002104","article-title":"Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies","volume":"104","author":"Azarova","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122308242481500_B4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4103\/0973-1482.73349","article-title":"Osteosarcoma of the mandible\u2013second cancer in a case of Hodgkin's lymphoma post-chemotherapy","volume":"6","author":"De","year":"2010","journal-title":"J Cancer Res Ther"},{"key":"2021122308242481500_B5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF02758571","article-title":"Primitive neuroectodermal tumor (PNET) as second malignancy after treatment of Hodgkin's disease","volume":"73","author":"Khadwal","year":"2006","journal-title":"Indian J Pediatr"},{"key":"2021122308242481500_B6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2008.00504.x","article-title":"Leukaemia cutis in a patient treated for breast cancer","volume":"50","author":"Weinel","year":"2009","journal-title":"Australas J Dermatol"},{"key":"2021122308242481500_B7","first-page":"1481","article-title":"Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study","volume":"91","author":"Moser","year":"2006","journal-title":"Haematologica"},{"key":"2021122308242481500_B8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122308242481500_B9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/589865","article-title":"Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin","volume":"47","author":"Martin-Carbonero","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021122308242481500_B10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/annonc\/mdl484","article-title":"Pegylated liposomal doxorubicin HCL (PLD; Caelyx\/Doxil): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer","volume":"18","author":"Andreopoulou","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122308242481500_B11","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308242481500_B12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jnci\/djq484","article-title":"Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer","volume":"103","author":"Muggia","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"suppl","key":"2021122308242481500_B13","article-title":"Multiple cases of squamous cell carcinoma of the tongue and oral cavity in patients treated with long-term pegylated liposomal doxorubicin (PLD) for ovarian cancer","volume":"29","author":"Cannon","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308242481500_B14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-010-1510-y","article-title":"Phase 1\/pharmacology study of intraperitoneal topotecan alone and with cisplatin: Potential for consolidation in ovarian cancer","volume":"68","author":"Andreopoulou","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122308242481500_B15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jmg.2006.048173","article-title":"Cancer risks in carriers of the BRCA1\/2 Ashkenazi founder mutations","volume":"44","author":"Kadouri","year":"2007","journal-title":"J Med Genet"},{"key":"2021122308242481500_B16","first-page":"2703","article-title":"Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers","volume":"29","author":"Jaworowska","year":"2009","journal-title":"Anticancer Res"},{"key":"2021122308242481500_B17","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1535-7163.MCT-11-0272","article-title":"BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin","volume":"10","author":"Safra","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2021122308242481500_B18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0027-5107(96)00022-X","article-title":"Mutagenic and carcinogenic properties of platinum-based anticancer drugs","volume":"355","author":"Sanderson","year":"1996","journal-title":"Mutat Res"},{"key":"2021122308242481500_B19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0277-5379(89)90047-3","article-title":"The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: A comparison with cisplatin","volume":"25","author":"Chibber","year":"1989","journal-title":"Eur J Cancer Clinical Oncol"},{"key":"2021122308242481500_B20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2021122308242481500_B21","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/annonc\/mdi204","article-title":"Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome?","volume":"16","author":"Jacobi","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122308242481500_B22","first-page":"243","article-title":"Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes","volume":"7","author":"Harrington","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122308242481500_B23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/09273940903374237","article-title":"Two successive ocular malignancies in the same eye of a HIV-positive patient: A case report","volume":"18","author":"Babu","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"2021122308242481500_B24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10384-009-0733-0","article-title":"Squamous cell carcinoma of the conjunctiva invading the orbit in a non-Hodgkin lymphoma","volume":"53","author":"Kwon","year":"2009","journal-title":"Jpn J Ophthalmol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0216","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/12\/1541\/41860522\/oncolo_17_12_1541.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/12\/1541\/41860522\/oncolo_17_12_1541.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T22:26:44Z","timestamp":1640298404000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/12\/1541\/6403285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,23]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,5,23]]},"published-print":{"date-parts":[[2012,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0216","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,12,1]]},"published":{"date-parts":[[2012,5,23]]}}}